Polycystic ovary syndrome and metformin in pregnancy

  title={Polycystic ovary syndrome and metformin in pregnancy},
  author={Anna E. Lilja and Elisabeth Reinhardt Mathiesen},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
The diagnostic criteria of polycystic ovary syndrome incorporate hyperandrogenism, polycystic ovaries, anovulation and irregular menstrual bleeding and the syndrome is a recognized reason behind infertility. The biguanide metformin has encouraging effects on several metabolic aspects of the syndrome, including insulin sensitivity, plasma glucose concentration and lipid profile. Moreover, metformin improves the ovarian function in women diagnosed with polycystic ovary syndrome. Hence, metformin… 

Role of Metformin on Recurrent Miscarriage and Other Pregnancy Complications in Women with Polycystic Ovarian Syndrome

It is found that using Metformin during pregnancy in women with PCOS may reduce the pregnancy loss and also reduce the risk of gestational diabetes, intrauterine growth retardation, IUGR & preterm labor.

Pregnancy outcomes among infertile patients with polycystic ovary syndrome treated with metformin

The study found that the abortion was reduced when metformin was used for ovulation induction before pregnancy and continued throughout the pregnancy, and found no evidence of any adverse clinical effects on the mother or the newborn when meetformin is continued through first trimester and entire pregnancy.

Effects of metformin use in pregnant patients with polycystic ovary syndrome

Since women with PCOS are more likely than healthy women to suffer from pregnancy-related problems like early pregnancy loss, gestational diabetes mellitus and hypertensive states in pregnancy, the use of metformin therapy in these patients throughout pregnancy may have beneficial effects on earlyregnancy loss and development of gestationalabetes.

Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes.

The role of metformin in pregnant women with obesity or who are overweight, on maternal and infant outcomes, including adverse effects of treatment and costs is evaluated.

Prevalence and Causes of Recurrent Abortion among Women in Beni-Suef Governorate

The data suggest that the rarer PGR allele may be associated with an increased likelihood of repeated abortions to its multi-factorial causes and couples who experience recurrent pregnancy loss may benefit from a medical evaluation and psychological support.

Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis.

A structured lifestyle modification programme to achieve weight loss should still be the first line treatment in obese women with or without PCOS, and the addition of high-dose metformin therapy to a structured lifestyles modification programme might contribute to more weight loss.

Lifestyle interventions for obese women before and during pregnancy: The effect on pregnancy outcomes

The aim of this thesis was to assess effects of weight-reduction interventions before, and lifestyle interventions during pregnancy on gestational weight gain and pregnancy related outcomes and estimate direct and indirect costs to society associated with obesity and weight gain in pregnancy.

Effects of blood pathological changes before TAI on pregnancy of dairy cows with anestrus and estrus

The objective of this study was to investigate the influence of plasma pathological changes before timed artificial insemination (TAI) on pregnancy of cows. The contents of estrogen (E2),

Effects of blood pathological changes before TAI on pregnancy of dairy cows with anestrus and estrus

The changes in E2, P4,hIS, Glu, and BDNF in the blood of natural estrus and natural anestrus cows affected the pregnancy after TAI, and the level of E2 in plasma may be used to assess the risk of negative pregnancy afterTAI.



Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology

This article focuses on the recent change in attitudes to polycystic ovarian syndrome arising from the link with insulin resistance—a concept that not only has major implications for the health of affected women but also offers a potential for new treatments.

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.

Metformin therapy during pregnancy in women with PCOS was safely associated with reduction in SAB and in GD, was not teratogenic, and did not adversely affect birthweight or height, or height and weight, weight, and motor and social development at 3 and 6 months of life.

Polycystic Ovary Syndrome in Adolescence

It is believed that hyperandrogenemia is the final common pathway for the development of adolescent PCOS, and a hypothesis to illustrate such is proposed.

Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study.

Maternal androgen levels were unaffected by metformin treatment in pregnant women with PCOS, and met formin treatment of pregnant PCOS women may reduce complications during pregnancy and in the post-partum period.

Obstetric outcome in women with polycystic ovarian syndrome.

It is concluded that PCOS slightly increases the risk for GDM, but does not have an important effect on the rate of premature delivery and pre-eclampsia.

Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements?

To achieve a safer prescribing environment, it is recommended that action be taken by the manufacturer of metformin to work with regulatory agencies on a European base to extend prescribing indications for met formin to women with PCOS.